News

30

Jun, 2022

Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11

Tags: ,

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine. The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London. This is one of the first large observational studies that uses Real-World Data evaluate the effectiveness of the Pfizer-BioNTech BNT162b2 (Comirnaty) vaccine in children aged 5-11 against the Omicron variant. The study compared rates of Covid-19-related outcomes in 94,728 vaccinated […]

READ MORE

30

Jun, 2022

c4c General Assembly

Tags:

Between 13th-15th June 2022, around 140 beneficiaries of the c4c consortium met in Ghent Belgium for the c4c General Assembly. This was the first time since 2019 that the consortium has been able to meet altogether in person. The General Assembly was a great opportunity for colleagues to meet again (or for the first time!) and to collaborate further for the benefit of the c4c network. The focus of this meeting was to provide an update on f the progress made and particularly to discuss plans for the future of […]

READ MORE

30

Jun, 2022

Il vaccino Pfizer-BioNTech BNT162b2 (Comirnaty) offre una protezione moderata dalla variante Omicron nei bambini dai 5 agli 11 anni

 

Padova, 30 giugno 2022 Il vaccino Pfizer-BioNTech BNT162b2 (Comirnaty) offre una protezione moderata dalla variante Omicron nei bambini dai 5 agli 11 anni. Lo dimostra un ampio studio appena pubblicato su The New England Journal of Medicine. Lo studio è stato condotto presso la più grande organizzazione sanitaria israeliana, il Clalit Health Services, in collaborazione con ricercatori dell’Università di Padova, dell’Università di Harvard e dell’University College London. Questo è uno dei primi grandi studi osservazionali che utilizza dati raccolti durante la pratica medica corrente, volto a valutare l’efficacia del vaccino […]

READ MORE

30

Jun, 2022

The D3 trial is open and recruiting fast!

Tags: ,

A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already recruited 57 participants in Uganda and Thailand. People living with HIV have to take medicines for life. Therefore, it is important to ensure that these medicines work well and continue to be safe to take for children and young people living with HIV. New approaches that make these anti-HIV medicines less toxic and easier to take could help improve their […]

READ MORE

30

Jun, 2022

Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11

Tags: , ,

Padua, 30 June 2022 – A large study on the effectiveness of the Pfizer Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine. The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London. This is one of the first large observational studies that uses Real-World Data evaluate the effectiveness of the Pfizer-BioNTech BNT162b2 (Comirnaty) vaccine in children aged 5-11 against the Omicron variant. The study compared rates of […]

READ MORE

28

Jun, 2022

SHIELD trial screens first two patients

Tags: ,

The first two participants of the SHIELD trial (PENTA-22) were screened by Dr. Renate Strehlau and her team at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa in June 2022.  SHIELD is the first paediatric trial on Fostemsavir, targeting children living with HIV that have developed resistance to two or more antiretroviral drug classes. SHIELD aims to evaluate the safety of fostemsavir when taken with optimized background antiretroviral therapy. The trial will also investigate the pharmacokinetics (which is investigating if the amount of drug in the blood  is sufficient to be […]

READ MORE

27

Jun, 2022

EMA updates guideline on the treatment of bacterial infections

Tags: ,

The European Medicines Agency (EMA) has published the final revised guideline on the evaluation of human medicines for the treatment of bacterial infections. The revised guideline reflects the outcome of recent discussions between regulators in the EU, United States and Japan on the development of new antimicrobial medicines. Among others, it includes recommendations on the clinical criteria for patient enrolment, the primary endpoint and the primary analysis in infection site-specific trials. Antimicrobial resistance (AMR) is a global threat that puts children’s health at great risk. WHO estimates that infections caused by multi-drug […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities